We provide top-quality service for directed differentiation of iPSCs into cardiomyocytes using our efficient induction protocol and reagents. We deliver ready-to-use, functional cardiomyocytes that are desirable in vitro models for high content toxicity and drug screening, and cell regeneration research. They are a feasible and physiologically relevant alternative to embryonic stem cells, primary cells, and animal models.
- High-quality cardiomyocytes
- Biomarkers: cTnT & SMA
- We can generate differentiated cardiomyocytes from iPSC derived from healthy or disease patient samples
- Fast turnaround time
Get iPSCs to genetically modify and further differentiate into immune cells? We offer fully customizable iPSC generation from human or non-human tissue samples, and our genome editing experts can use CRISPR or TARGATT™ to genetically alter the iPSCs to fit your project requirements. If you need to expedite your experimental timeline, ASC also offers off-the-shelf cardiomyocytes. Contact us today to find the best solution for your projects.
Products and Services
Viewing 1-2 of 2 products
Timelines: 4-6 weeks
- Recovery, Expansion and Validation of iPSCs/ESCs: estimated 3 weeks
- Cardiomyocytes Differentiation: estimated 2-4 weeks
- Characterization of differentiated cells by immunocytochemical (ICC) staining: 2 biomarkers (cTNT; SMA): estimated 2-4 days